In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.
The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.
The firm beat the consensus Wall Street estimates on the top and bottom lines as the diagnostics segment saw revenues grow 20 percent year over year.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent
The deal gives Beckman Coulter non-exclusive distribution rights in the US and Canada to the NGS library preparation kits for cell-free DNA in plasma.
The Beckman Coulter unit provides genomic sequencing solutions to healthcare businesses, governments, and academia around the world.
IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.
Following a beta evaluation of the system, a virology lab in Sheffield, UK, ran a workflow assessment and found improvements with the system.
The DxN Veris was recently launched as a CE-marked product with a menu of viral load tests, and will launch in a few years in the US with STD and HAI assays.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.